A5038988779- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- NF-κB Signaling Pathways
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Research in Cotton Cultivation
- Single-cell and spatial transcriptomics
- Cancer, Lipids, and Metabolism
- Integrated Circuits and Semiconductor Failure Analysis
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Biosimilars and Bioanalytical Methods
- Virus-based gene therapy research
- Chromatin Remodeling and Cancer
- Genomics and Chromatin Dynamics
- Growth Hormone and Insulin-like Growth Factors
- Lipid metabolism and biosynthesis
- Cancer Research and Treatments
- Cholesterol and Lipid Metabolism
- Advanced Fluorescence Microscopy Techniques
- Urticaria and Related Conditions
The University of Texas MD Anderson Cancer Center
2017-2025
University of Houston
2018-2023
St. Luke's Magic Valley Medical Center
2020
Family Medicine Residency of Idaho
2020
SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. among most recurrently mutated genes human cancer, including ∼30% germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression lymphomagenesis. Furthermore, monoallelic deletion drove GC hyperplasia...
Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in relapsed/refractory large B lymphoma (rrLBCL) but associated with toxicities that delay recovery. While the biological mechanisms of cytokine release syndrome and neurotoxicity have been investigated, pathophysiology poorly understood for prolonged cytopenia, defined as grade ≥3 cytopenia lasting beyond 30 days after CAR infusion. We performed single-cell RNA sequencing bone marrow samples from...
Background Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and the likely source deadly, relapsed disease. While cell transplant serves as proof-of-principle that AML LSCs can be eliminated by immune system, translation existing immunotherapies to has been met with limited success. Consequently, understanding exploiting unique immune-evasive mechanisms is critical. Methods Analysis datasets primary patient samples revealed CD200 a...
Abstract Introduction. We have recently demonstrated that pro-tumoral SIRPα+ macrophages may mediate resistance to lenalidomide and rituximab (R2) in patients (pts) with relapsed or refractory (RR) B-cell non-Hodgkin lymphoma (B-NHL). Evorpacept (ALX148) is a novel high-affinity CD47 blocker abrogates the ‘do-not-eat-me signal’ provided macrophages. In phase I trial including 33 pts RR B-NHL it was well tolerated combination rituximab. hypothesized evorpacept R2 will be synergistic, safe...
Abstract The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic receptor signaling and associated with poor outcomes when treated standard therapy. In ABC-DLBCL, MALT1 a core enzyme that constitutively stimulation the or gain-of-function mutations in upstream components pathway, making it an attractive therapeutic target. We discovered novel small-molecule inhibitor, ABBV-MALT1, potently shuts down selectively ABC-DLBCL preclinical models...
Assays based on Förster resonance energy transfer (FRET) can be used to study many processes in cell biology. Although this is most often done with microscopy for fluorescence detection, we report two ways measure FRET living cells by flow cytometry. Using a conventional cytometer and the "3-cube method" intensity-based calculation of efficiency, measured enzymatic activity specific kinases expressing genetically-encoded reporter. For both AKT protein kinase A, method time-course,...
Our recent study has implicated bradykinin (BK) signaling as being of pathogenic importance in lupus. This aims to investigate the biomarker potential BK peptides, and BK-des-arg-9, lupus other rheumatic autoimmune diseases. Sera from systemic erythematosus (SLE) patients healthy subjects were screened for BK-des-arg-9 by liquid chromatography-mass spectrometry metabolomics. Serum 6-mo-old C57BL/6 mice three murine strains also two peptides Given promising initial screening results,...
// Mallika Tripathy 1 , Amy Bui Jared Henderson Jeffrey Sun Christian Rutan Woods Soumya Somani Thao Doan Anto Sam Crosslee Louis Titus and Chandra Mohan Department Biomedical Engineering, University of Houston, TX 77204, USA Correspondence to: Mohan, email: cmohan@central.uh.edu Keywords: FAAH; breast cancer; cancer therapy; apoptosis Received: May 23, 2023     Accepted: September 21, Published: October 31, 2023 Copyright: © et al. This is an open access article...
Abstract Multiple therapies with immune mechanisms of action such as CAR T-cells and bispecific antibodies are now approved for relapsed/refractory large B-cell lymphoma (rrLBCL). The efficacy these is likely influenced by microenvironment (LME) characteristics, but have not been directly characterized in a comprehensive fashion. We therefore performed single-nucleus multiome (RNA + ATAC), bulk RNA, WES 119 biopsies from 114 patients to capture both hematopoietic non-hematopoietic cell...
<p>Antiapoptotic complex formation in ABC-DLBCL xenografts after ABBV-MALT1 monotherapy</p>
<p>Efficacy of ABBV-MALT1 across non-GCB PDX models</p>
<div>Abstract<p>The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic receptor signaling and associated with poor outcomes when treated standard therapy. In ABC-DLBCL, MALT1 a core enzyme that constitutively stimulation the or gain-of-function mutations in upstream components pathway, making it an attractive therapeutic target. We discovered novel small-molecule inhibitor, ABBV-MALT1, potently shuts down selectively ABC-DLBCL...
<p>Supplementary Materials and Methods</p>
<div>Abstract<p>The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic receptor signaling and associated with poor outcomes when treated standard therapy. In ABC-DLBCL, MALT1 a core enzyme that constitutively stimulation the or gain-of-function mutations in upstream components pathway, making it an attractive therapeutic target. We discovered novel small-molecule inhibitor, ABBV-MALT1, potently shuts down selectively ABC-DLBCL...
<p>Excel Workbook RNASeq</p>
<p>Excel Workbook ABBV-MALT1 Pharmacology</p>